People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Spinal Singularity, Inc. | — | Biotechnology | Seed | $4.9M | $88.6M | 2016 |
| Geneva C.C., Inc. | — | Other | Pre-Seed | $950K | $1.6M | — |
Christopher Jennings at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Jennings on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kenneth Baker | 1 | 3 |
| Derek Herrera | 1 | 2 |
| Andrew Gilbert | 1 | 2 |
| Bill Colone | 1 | 2 |
| David Kaysen | 1 | 2 |
| Ronald J. Anania | 1 | 1 |
| Thomas B. Tierney | 1 | 1 |
| Richard LaVoie | 1 | 1 |
| Robert H. Manion, III | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.